极光vp n官网入口

极光vp n官网入口

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

极光vp n官网入口

Learn More
Folded page of a newspaper

极光vp n官网入口

极光vp n官网入口

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

极光vp n官网入口

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

极光vp n官网入口

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

极光vp n官网入口

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

极光vp n官网入口

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

极光vp n官网入口

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

芒果pvn  苹果好用的免费梯子  sgreen科学加速器  surf官网  bluelight安卓版  软件合集分享链接汇总大全  云墙加速器官网